Axcan releases European Phase III PYLERA trial results; BioSante goes back to GVAX;

> Axcan Pharma has released the results of its European PYLERA® Phase III trial comparing the rate of Helicobacter pylori (H. pylori) eradication after OBMT (Omeprazole, Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline) quadruple therapy with a 3-in-1 capsule to H. pylori eradication rate after OAC (Omeprazole, Amoxicillin, and Clarithromycin). The study supports the European registration of PYLERA for the eradication of H. pylori, a bacterium responsible for the majority of cases of duodenal ulcer disease. Release

> BioSante Pharmaceuticals is reinitiating development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer. Patients are expected to be treated in a Phase II clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Biosante release 

> Goodwin Biotechnology and Hyprocell will collaborate on the creation of a business model integrating cDNA synthesis, cloning into mammalian expression vector, transfection, clone selection and stable cell line development seamlessly with cell banking, upstream/downstream process development and GMP manufacturing. Release

> Nanobiotix, which develops innovative therapeutic products for cancer using nanotechnologies including its "nanoXray"  therapeutic platform, has raised US $11 million from a new and existing syndicate of investors including CIC Vizille Capital Innovation. Announcement 

> The Rite Aid drug store chain will carry Oragenics' oral care probiotic mint product, EvoraPlus. ProBiora3, the active ingredient in EvoraPlus is composed of three strains of beneficial bacteria that help maintain an optimal balance in the mouth. Release

> Spring Creek Capital Corporation has signed a strategic licensing agreement with McCoy Enterprise for its patented oral spray drug delivery system which delivers medication via the inner lining of the cheek. According to the company, current market applications for the technology include insulin delivery for diabetes and calcitonin delivery for osteoporosis. Release 

> EyeGate Pharma has established a research collaboration with GlaxoSmithKline to evaluate the delivery of several GSK therapies for ocular disease to the tissues of the eye using the EyeGate® II non-invasive "iontophoresis" delivery system. Announcement

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.